Oxford BioMedica plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Oxford BioMedica plc
Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.
Brian Yang, Dexter Yan and guest speaker Kevin Grogan from the UK discuss Shanghai's latest policy to spur biopharma investment, the US House's recent draft bill to restrict bio service providers from China, and multinationals' strategies in China and views on Chinese innovation.
Avance Clinical’s CEO talks to Scrip about green shoots in US biotech funding, potential partnering in the AI space, the Australia rapid-start draw for early phase trials and the transition in the study design landscape in oncology for first-in-human trials.
A draft bill from the US House related to national security issues sent WuXi Biologics' shares tumbling over concerns around increased US scrutiny of Chinese firms, which a company clarification did little to dispel.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Oxxon Therapeutics Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.